Solventum
SOLV · What the business does, what can go wrong, and how options sellers approach it
What it does
Solventum is a healthcare products and technology company. It was spun off from 3M and trades as its own public company. It makes medical supplies, dental and orthodontic products, and software used by hospitals and health systems.
Its business is organized around a few areas. MedSurg covers items like wound care, I.V. site management, surgical supplies and medical tapes. Dental Solutions sells products such as orthodontic brackets, restorative materials and bonding agents. Health Information Systems offers software for clinical documentation, coding automation and related data tools.
How it makes money
Solventum sells products and software to hospitals, clinics, dental practices and other healthcare customers. Much of the product revenue is recurring in nature, because supplies like dressings and dental consumables are used over and over. The software side typically earns revenue through licenses and subscriptions. The United States is the largest market, with international sales making up the rest.
Why investors own it
- Exposure to healthcare demand, which tends to be steadier than many other parts of the economy.
- A broad catalog of consumable products with repeat purchasing.
- A software segment that can add higher-margin, recurring revenue.
- Potential for improvement as an independent company that sets its own strategy and capital priorities.
What can go wrong
- Heavy competition from large medical device, supply and dental companies.
- Pricing pressure from hospital purchasing groups and insurers.
- Debt taken on during the separation can limit flexibility.
- Execution risk from operating as a standalone company after the separation from 3M.
- Product liability, regulatory and legal issues can arise in medical products.
- Dental spending can slow when consumers delay elective care.
What to watch
- Organic sales growth by segment
- Operating margin trends
- Debt levels and progress on paying them down
- Cost savings and separation-related spending
- Regulatory actions or product recalls
- Hospital procedure volumes and dental visit trends
- Growth in software and recurring revenue
Options income angle
Options on SOLV are generally available across several expirations, but liquidity is usually thinner than for the largest healthcare names. Check open interest and bid-ask spreads before relying on any strike.
Implied volatility tends to rise around quarterly earnings, guidance changes, and news about debt, portfolio changes or litigation. One caution for premium sellers: a stock can gap sharply on earnings or guidance, which can quickly overwhelm the premium collected on a covered call or cash-secured put.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 27, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
Solventum's 2025 results were reshaped by the September sale of its Purification and Filtration business, which produced a large one-time gain and cut debt. The underlying business grew modestly while margins were squeezed by tariffs and the costs of separating from 3M. The filing stresses that the company still depends on 3M for key materials and indemnities.
How the business did
- Net sales were $8,325 million, up 0.9% as reported and 3.3% on an organic basis (which strips out currency effects, acquisitions and divestitures). The sold business reduced reported sales.
- Operating income was $2,181 million versus $1,036 million a year earlier. The gain on the sale was a net $1.5 billion, which explains most of the jump.
- Cost of product rose to 53.6% of product sales from 50.0%, driven by new tariffs of approximately $55 million, a full year of inventory sourced from 3M, and higher logistics costs. MedSurg operating income fell to $810 million from $887 million, while Health Information Systems rose to $496 million from $431 million.
- Cash provided by operating activities was $369 million versus $1,185 million, reflecting separation costs and sale-related activity. The company repaid $2.0 billion of senior notes via tender offers and $870 million of a term loan. Cash and cash equivalents were $878 million.
- The effective tax rate was 9.2% versus 20.9%, mainly due to the sale.
Risks specific to this company
- Dependence on 3M for supply. 3M is the sole source of certain materials used in products that accounted for approximately $3 billion of fiscal 2025 revenue, including approximately $2 billion tied to a process proprietary to 3M. The filing says no substitute has been identified and the company cannot make these materials itself.
- Debt. The company had approximately $5 billion of outstanding indebtedness. The filing says interest payments take a substantial portion of operating cash flow and could limit dividends, buybacks and acquisitions.
- Spin-off tax exposure. If the 2024 spin-off from 3M lost its tax-free status, the company and shareholders could face significant tax. Under the Tax Matters Agreement the company must indemnify 3M in some cases, and it restricts certain equity issuances and takeovers.
- PFAS (long-lasting "forever chemicals"). 3M's indemnity covers PFAS-related product claims only for sales through 2025. Some Solventum products still contain third-party PFAS components, so later sales are not covered.
- 3M share sales. 3M holds 14.8% of the common stock and is expected to sell it within five years. The filing warns that sales or the expectation of them could pressure the stock price.
- Tariffs and geopolitics. Trade actions have already hit the company and its suppliers, and the filing flags U.S.-China tensions. It also notes supply disruption from Russian raw material suppliers.
What management is watching
- Standalone transition. Capital spending of $379 million is focused on separation work, including moving manufacturing and sourcing away from 3M. The multiyear "Transform for the Future" restructuring aims to cut costs.
- Acera Surgical. The December 2025 purchase cost $696 million net of cash acquired, plus a possible $125 million payment tied to a sales milestone. The filing frames it as a push into regenerative wound care.
- Demand themes. Management points to an aging population, care shifting to lower-cost sites, and digital and AI-enabled tools. It also cites the risk of AI-enabled competitors, especially for Health Information Systems.
- Use of cash. Discretionary cash may go to acquisitions, share repurchases or debt repayment. A commercial paper program allows up to $2.0 billion of short-term borrowing, with none outstanding.
- Measures to watch. Management directs investors to organic sales change, constant-currency growth and segment operating income. It treats geographic data as a secondary measure.
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed November 5, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
Third-quarter sales were $1,949 million, down 7.0% from $2,096 million, as customers worked down inventory they had bought early ahead of the company's July 2026 U.S. ERP (enterprise software) rollout. Operating income was $68 million against $1,690 million a year earlier, when a one-time gain from selling the Purification and Filtration business inflated the result. The company also announced it intends to pursue a separation of its Health Information Systems business.
How the business did
- Sales: Organic sales (which exclude currency and acquisitions or divestitures) fell 2.8% in the quarter. The company said about $125 million of customer orders were pulled into the second quarter. For nine months, sales were $6,165 million, down 2.6% as reported, with organic growth of 2.9%.
- Segments: MedSurg sales were $1,211 million, up 0.4%, with organic sales down 2.8%. Dental Solutions fell 6.7% to $317 million, and its operating margin was 20.1% of sales versus 25.7%. Health Information Systems rose 3.3% to $356 million, helped by adoption of Solventum 360 Encompass.
- Profit drivers: Cost of product rose to 53.8% of product sales from 53.1%, on freight and warehousing costs tied to the ERP rollout. SG&A (selling, general and administrative expense) rose to 41.7% of sales from 37.2%, on restructuring costs and lower sales. For nine months, IEEPA tariff refunds of $100 million received in 2026 lowered cost of product. The company had requested approximately $120 million in refunds and had recovered $118 million by quarter end.
- Cash and capital return: Operating cash flow for nine months was $215 million versus $274 million, held back by higher receivables, 3M transition exit payments and incentive pay. Cash and cash equivalents were $451 million, versus $878 million at December 31, 2025. Activity in financing was mainly a share repurchase program that began this year. Interest expense, net fell to $68 million from $89 million on lower debt.
What management is watching
- ERP and inventory: The company ties the quarter's weaker sales and higher costs to the July ERP deployment and the customer inventory reduction that followed.
- Tariffs: After the Supreme Court ruled the IEEPA does not authorize tariffs, the U.S. put new tariffs in place under Sections 122, 301, 338 and 232. The company says it will keep monitoring developments.
- Cost programs and portfolio: Management points to its Transform for the Future restructuring savings and an SKU rationalization program, which trims product variety and weighed on growth, mostly in Infection Prevention and Surgical Solutions.
- Measures cited: The company directs investors to organic sales change, constant-currency change and segment operating income. The MD&A gives no numerical full-year outlook.
New or changed risks
- The only new risk factor concerns the review of strategic alternatives for the Health Information Systems business. It may not lead to any transaction, and any transaction pursued may not close on time or at all.
- The company says it could abandon the review, choose a different structure, or take no action.
- The process may create uncertainty for customers and employees and divert management attention. Costs may be incurred whether or not a deal happens.
Follow SOLV in Kortex
The Kortex app shows SOLV's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.